News articles about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.3905465175404 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- -$0.66 Earnings Per Share Expected for Zynerba Pharmaceuticals Inc (ZYNE) This Quarter (americanbankingnews.com)
- Zynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Zynerba Pharmaceuticals (ZYNE) Given a $23.00 Price Target at HC Wainwright (americanbankingnews.com)
- Insider Buying: Zynerba Pharmaceuticals Inc (ZYNE) President Acquires 3,800 Shares of Stock (americanbankingnews.com)
- Zynerba Pharmaceuticals Inc (ZYNE) Chairman Armando Anido Purchases 15,000 Shares (americanbankingnews.com)
ZYNE has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $20.00 price objective on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, April 25th. Canaccord Genuity reduced their price objective on shares of Zynerba Pharmaceuticals from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 3rd. ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. HC Wainwright set a $23.00 price objective on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, August 6th. Finally, Oppenheimer reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, May 8th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $17.06.
Shares of NASDAQ:ZYNE traded up $0.07 during midday trading on Friday, reaching $6.50. The company’s stock had a trading volume of 244,578 shares, compared to its average volume of 745,150. The company has a market capitalization of $113.32 million, a PE ratio of -2.62 and a beta of 4.44. Zynerba Pharmaceuticals has a 12-month low of $5.42 and a 12-month high of $15.14.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its earnings results on Thursday, August 2nd. The company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.12). analysts expect that Zynerba Pharmaceuticals will post -3 EPS for the current fiscal year.
In other news, Chairman Armando Anido acquired 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 6th. The shares were bought at an average cost of $5.96 per share, with a total value of $89,400.00. Following the transaction, the chairman now owns 352,512 shares of the company’s stock, valued at approximately $2,100,971.52. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Michael Rapp acquired 5,885 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were purchased at an average cost of $10.45 per share, for a total transaction of $61,498.25. The disclosure for this purchase can be found here. Insiders have purchased a total of 33,203 shares of company stock worth $223,753 over the last three months. 12.67% of the stock is currently owned by insiders.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.